Elicera Therapeutics AB (publ) announced that it has received a so called "Notice of Allowance" from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the patent can be kept in force until 2036.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 SEK | -2.11% | -2.11% | -79.61% |
Mar. 28 | Elicera Therapeutics AB Announces Director Changes | CI |
Mar. 06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.61% | 3.06M | |
+27.09% | 681B | |
+21.85% | 556B | |
-4.82% | 361B | |
+17.22% | 325B | |
+5.71% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.89% | 157B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform